-
Cycling industry bets on smart bikes to boost sales
-
'High-strung' camels race in Australian outback
-
In Idaho, the next generation of US nuclear reactors nears reality
-
Algeria and Austria reach World Cup knockouts after 3-3 thriller
-
Africa the winner of expanded World Cup amid mixed fortunes for minnows
-
DR Congo advance but Iran out as wild World Cup group stage wraps
-
Asia's vendors grapple with rising costs of ever-present plastics
-
Austria and Algeria reach World Cup knockouts after 3-3 thriller
-
Messi scores again as Argentina head into World Cup last 32 on a high
-
Where are they? Dogs disappear before South Korea meat ban
-
Wissa proud to deliver World Cup joy to war-torn DR Congo
-
China's bull wrestlers fight to keep tradition alive
-
South Korea's 'dismal' World Cup ends in group phase
-
England top group to set up DR Congo World Cup clash, Portugal held
-
Colombia and Portugal through to World Cup last 32 after thrilling draw
-
England moving on at World Cup but questions linger
-
Wissa sends DR Congo into World Cup last 32 clash with England
-
Venezuela quakes kill 1,400 as time running out to find survivors
-
A painful wait by a pile of rubble in quake-hit Venezuela
-
Australia World Cup goalkeeper Patrick Beach has beach named after him
-
Tuchel delighted to have Bellingham in 'sweet spot' for England at World Cup
-
Take brutally hot weather seriously, heatstroke survivor warns
-
Bellingham says 'job done' but England must improve at World Cup
-
Australia boosts shark-spotting drone coverage at Sydney beaches
-
Trump threatens to annihilate Iran after new exchange of attacks
-
Scotland boss Clarke resigns after World Cup exit confirmed
-
Scotland boss Clarke resigns after World Cup exit confirmed: official
-
Kane, Bellingham on target as England win World Cup group
-
Kane, Bellingham on target as England clinch top spot
-
Croatia battle past Ghana to sew up World Cup Last 32 spot
-
Bellingham, Kane score as England beat Panama to reach World Cup last 32
-
US, Iran clash, putting fragile deal under growing strain
-
Canada's Davies 'available' for historic knockout clash
-
Ryu takes one-shot lead over Henderson at Women's PGA Championship
-
Hovland seizes one-shot PGA Travelers lead over Scheffler
-
Jangoo and Chase put West Indies in control against Sri Lanka
-
Mauvaka double inspires Toulouse to fourth-straight Top 14 in storm-impacted final
-
World Cup star Gakpo requests privacy after death of unborn son
-
Solidarity, sadness among Venezuelans made destitute by quake
-
Aid planes landing at partially reopened Venezuela airport after quakes
-
Iran says US violated peace deal as both sides attack
-
Spain's Williams hits out at Uruguay over World Cup injury
-
'We need help': Venezuelans furious at slow official response to quakes
-
World's largest particle smasher halts for upgrade to boost hunt for dark matter
-
Venus Williams relishes 'very special' Wimbledon reunion with sister Serena
-
Ex-Olympic medallist Canderloro elected French Ice Sports chief
-
Ravindra leads New Zealand rally in England finale after Archer's double strike
-
Prince Harry and family to stay at royal residences on UK visit
-
Wimbledon 'towel thief' Swiatek back on the trophy hunt
-
'Why not?': Cape Verde eye seismic World Cup shock against Argentina
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Click here to register
SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc.(NASDAQ:JAGX)
Participation Instructions for Webcast
When: Friday, April 10, 2026 at 8:30 a.m. Eastern
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar's website: (click here)
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will hold an investor webcast on April 1, 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
R.Lee--AT